CME Case Challenge: Clinical Management of PNH and AML in an Era of Novel Therapies

CME Case Challenge: Clinical Management of PNH and AML in an Era of Novel Therapies is organized by Cleveland Clinic Foundation Center for Continuing Education.

Release Date: 9/11/2019
Expiration Date: 09/11/2021

Target Audience:
This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Accreditation:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians. The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Description:
This activity will provide an up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with paroxysmal nocturnal hemoglobinuria (PNH) and acute myeloid leukemia (AML).

Objectives:
• Critically appraise results of research on the evolving role of chimeric antigen receptor-T cell (CAR-T) therapy in myeloid malignancies.
• Provide an in-depth overview of the efficacy and side effects of combination therapies for acute myeloid leukemia.
• Describe the diagnostic complexities and treatment options for paroxysmal nocturnal hemoglobinuria (PNH).
• Describe the genomic mutations in overlap syndromes, prognostic implications, and treatment options.
• Identify the most recent indications and strategies for bone marrow transplant in patients with acute myeloid leukemia or myelodysplastic syndrome.